Systematic discrimination and human rights violations against minority communities in Sri Lanka are not new in the country’s political and social realm. The most recent of such violations have been brought to the forefront during the outbreak of the COVID-19 pandemic, exposing the State’s skewed practices in its wake. This will be an endeavor to examine how a purely tolerant (in its classical sense) society is ultimately an unrealistic, and moreover destructive, standard to strive towards. By analyzing various viewpoints on what tolerance truly means within the context of Sri Lanka’s treatment of its religious minorities, the ideology itself comes to scrutiny. A system of checks and balances is pertinent by both state and non-state actors for the survival of a society and the ultimate protection of the religious minorities in a country where they are routinely marginalized and discriminated against, specifically in the context of the rise of religious intolerance faced by the M
December 21, 2020 Oral XPOVIO® Approval as Combination Therapy in Patients with Multiple Myeloma After At Least One Prior Therapy Significantly Expands the XPOVIO® Addressable Patient Population - Oral XPOVIO® is Now the Only Approved Multiple Myeloma Drug Indicated as Part of a Once-Weekly Bortezomib Combination Regimen - First Multiple Myeloma Drug with a New Mechanism of Action Approved by the FDA in the Second-Line Setting Since 2016 - FDA Approval Comes Approximately Three Months Ahead of Target PDUFA Date -
SHANGHAI and HONG KONG, Dec. 21, 2020 /PRNewswire/ Antengene Corporation Limited ( Antengene , SEHK: 6996.HK) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) submitted by its partner Karyopharm Therapeutics Inc. (Nasdaq: KPTI) for oral XPOVIO
(2)
DJ EQS-News: Antengene Announces its U.S. Partner, Karyopharm Therapeutics Inc., has received FDA Approval of XPOVIO(R) (Selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Therapy
EQS-News / 21/12/2020 / 15:21 UTC+8 Antengene Announces its U.S. Partner, Karyopharm Therapeutics Inc., has received FDA Approval of XPOVIO(R) (Selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Therapy Oral XPOVIO(R) Approval as Combination Therapy in Patients with Multiple
Myeloma After At Least One Prior Therapy Significantly Expands the XPOVIO(R) Addressable Patient Population - Oral XPOVIO(R) is Now the Only Approved Multiple Myeloma Drug Indicated
TodayIR: Antengene Announces its U S Partner, -2- finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
SHANGHAI and HONG KONG, Dec.18, 2020 /PRNewswire/ Antengene Corporation Limited ( Antengene , SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in class therapeutics in hematology and oncology, announced that the National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application for ATG-010 (selinexor), an oral Selective Inhibitor of Nuclear Export compound, in combination with bortezomib and dexamethasone for the treatment of patients with relapsed/refractory multiple myeloma (rrMM) in China.
The trial is a Phase 3 randomized, controlled, open-label, multicenter clinical trial, aiming to evaluate the efficacy and safety of ATG-010, bortezomib and dexamethasone (SVd) regimen against bortezomib and dexamethasone (Vd) regimen in Chinese adult patients with rrMM who have received one to three prior lin